ClinicalTrials.gg
CompletedNCT05972044Updated Feb 10, 2026

A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)

A Phase 3 interventional study of Solriamfetol 150 mg and Solriamfetol 300 mg in ADHD, sponsored by Axsome Therapeutics, Inc.. Completed at 42 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Axsome Therapeutics, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 9 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Feb 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
516
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States — 98 open to participants now, 116 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · United States.

Enrollment
26th of 706
516 · median 70
Started
2023
with 29 others
Phase 3
121 of 807
4 open now
Registered
703rd of 807
by date

Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, this one is the 26th largest by enrollment of the 706 interventional ones that give a count, is one of 30 that started in 2023, is one of 121 in phase 3, and was the 703rd registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

98 of the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, or all of them as a file.
02

Study summary

FOCUS (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with ADHD.

Read the detailed description

Eligible subjects must have a primary diagnosis of ADHD based on the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) criteria. Subjects will be randomized in a 1:1:1 ratio to be treated with solriamfetol 150 mg, solriamfetol 300 mg, or placebo, once daily for 6 weeks.

03

Conditions studied

  • ADHD

Keywords

  • Attention deficit hyperactivity disorder
  • ADHD
  • Solriamfetol
  • Sunosi
  • Axsome
  • Non-stimulant therapy
  • Dopamine norepinephrine reuptake inhibitor
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary diagnosis of ADHD according to criteria.
  • Provides written to participate in the study before the conduct of any study procedures.
  • Male or female, aged 18 to 55 inclusive.

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to solriamfetol/Sunosi, through either a clinical study or prescription.
  • Unable to comply with study procedures.
  • Medically inappropriate for study participation in the opinion of the investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
516 participants (actual)

Study arms

  • Experimental
    Solriamfetol 150 mg

    Up to 6 weeks

    Drug: Solriamfetol 150 mg

  • Experimental
    Solriamfetol 300 mg

    Up to 6 weeks

    Drug: Solriamfetol 300 mg

  • Placebo comparator
    Placebo

    Up to 6 weeks

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change from Baseline to Week 6 in the AISRS total score

    Adult ADHD Investigator Symptom Report Scale (AISRS)

    Time frame: 6 weeks

07

Study locations

42 sites
  • Clinical Research Site
    Encino, California 91316, United States
  • Clinical Research Site
    Garden Grove, California 92845, United States
  • Clinical Research Site
    Newport Beach, California 92660, United States
  • Clinical Research Site
    Riverside, California 92506, United States
  • Clinical Research Site
    Santa Ana, California 92705, United States
  • Clinical Research Site
    Sherman Oaks, California 91403, United States
  • Clinical Research Site
    Torrance, California 90504, United States
  • Clinical Research Site
    Walnut Creek, California 94596, United States
  • Clinical Research Site
    Colorado Springs, Colorado 80910, United States
  • Clinical Research Site
    Clermont, Florida 34711, United States
  • Clinical Research Site
    Doral, Florida 33122, United States
  • Clinical Research Site
    Gainesville, Florida 32607, United States
  • Clinical Research Site
    Jacksonville, Florida 32256, United States
  • Clinical Research Site
    Lauderhill, Florida 33319, United States
  • Clinical Research Site
    Miami Lakes, Florida 33016, United States
  • Clinical Research Site
    Orlando, Florida 32801, United States
  • Clinical Research Site
    Marietta, Georgia 30060, United States
  • Clinical Research Site
    Overland Park, Kansas 66210, United States
  • Clinical Research Site
    Boston, Massachusetts 02131, United States
  • Clinical Research Site
    Saint Charles, Missouri 63304, United States
  • Clinical Research Site
    Lincoln, Nebraska 68526, United States
  • Clinical Research Site
    Las Vegas, Nevada 89102, United States
  • Clinical Research Site
    Las Vegas, Nevada 89128, United States
  • Clinical Research Site
    Berlin, New Jersey 08009, United States
  • Clinical Research Site
    Cherry Hill, New Jersey 08002, United States
  • Clinical Research Site
    Princeton, New Jersey 08540, United States
  • Clinical Research Site
    Mount Kisco, New York 10549, United States
  • Clinical Research Site
    New York, New York 10128, United States
  • Clinical Research Site
    Raleigh, North Carolina 27609, United States
  • Clinical Research Site
    Cincinnati, Ohio 45219, United States
  • Clinical Research Site
    Kettering, Ohio 45439, United States
  • Clinical Research Site
    Oklahoma City, Oklahoma 73116, United States
  • Clinical Research Site
    Media, Pennsylvania 19063, United States
  • Clinical Research Site
    North Charleston, South Carolina 29405, United States
  • Clinical Research Site
    Memphis, Tennessee 38119, United States
  • Clinical Research Site
    Austin, Texas 78737, United States
  • Clinical Research Site
    Bellaire, Texas 77401, United States
  • Clinical Research Site
    Dallas, Texas 75243, United States
  • Clinical Research Site
    Dallas, Texas 75251, United States
  • Clinical Research Site
    San Antonio, Texas 78229, United States
  • Clinical Research Site
    Draper, Utah 84020, United States
  • Clinical Research Site
    Everett, Washington 98201, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Feb 2025, 19 months.

Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 19 months is above that.

Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2023
First posted
Aug 2, 2023
StartActual
Jul 6, 2023
Primary completionActual
Feb 7, 2025
CompletionActual
Mar 14, 2025
Results delay requested
Feb 5, 2026
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05972044
Responsible party
Sponsor
First posted
Aug 2, 2023
Start date
Jul 6, 2023
Primary completion
Feb 7, 2025
Completion
Mar 14, 2025
Last update
Feb 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solriamfetol

Start the discussion